| 摘要 |
PROBLEM TO BE SOLVED: To provide novel liposomes comprising Gd.DOTA.DSA with reduced toxicity, improved safety and enhanced MR signal-enhancing effect.SOLUTION: The present invention provides liposomes comprising Gd.DOTA.DSA (gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N'-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid), characterized in that the liposomes further comprise a neutral, fully saturated phospholipid component. |
